AACR 2024: A Novel Automated Platform for Rapid Manufacturing of CAR-T Cells

AACR 2024 poster introducing A new Automated MARS Platform for Rapid Manufacturing of CAR-T Cells by Applied Cells

Autologous cell therapy using T cells that are genetically modified to express a chimeric antigen receptor (CAR) has yielded durable responses in patients with cancers. However, globally only a small fraction of eligible patients are privileged to receive the treatment. High cost and long manufacturing time contribute to the key limitations prohibiting a broad adoption […]

Column-Free CD14+ Monocyte Isolation using 50nm Superparamagentic Beads on MARS® Bar

Application note showcasing Column-Free Monocyte Isolation using 50nm Superparamagentic Beads on MARS® Bar

Dendritic cells are professional antigen-presenting cells and they play a key role in the regulation of immune responses. Dendritic cells are widely used as vaccines and drugs for cancer treatment in a large number of trials. Macrophages are essential innate immune cells and when activated, macrophages can mediate the phagocytosis of dangerous cells or materials […]

Column-Free T cell Isolation using 50nm Superparamagentic Beads on MARS® Bar

Application note showcasing Column-Free T cell Isolation using 50nm Superparamagentic Beads on MARS® Bar

 The therapeutic efficacy of CAR T cells has been firmly established in hematologic malignancies and the key is to develop a low-cost manufacturing process to enable the wide adoption of the therapy. T cell isolation being upstream process for CAR T cell manufacturing has significant impact on the quality of the T cells and the […]

CD34+ Cell Isolation from Cord Blood MNC

Application note highlighting benefits of CD34+ Cell Isolation from Cord Blood Mononuclear Cells (MNC) from Applied Cells MARS Bar

 CD34+ cells offer valuable insights into hematopoiesis, hematological disorders, and regenerative medicine. They have potential in cancer therapies, autoimmune diseases, and genetic disorders. Isolating CD34+ cells from Cord Blood Mononuclear Cells (MNC) is crucial for research in hematopoietic stem cell biology and therapeutic advancements. MARS® Platform ensures the enrichment of CD34+ cells, enhancing purity, viability, […]

CD138+ Plasma Cell Enrichment directly from Bone Marrow

Application note highlighting CD138+ Plasma Cell Enrichment directly from Bone Marrow with MARS platform

CD138 expression is a crucial marker in diagnosing plasma cell tumors and Multiple Myeloma cells. Traditionally, the evaluation of plasma cells from bone marrow involves a time-consuming and labor-intensive density gradient separation method using ficoll. However, this method leads to the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and […]

Simple magnetic cell separation enabled by an automated, closed system for both autologous and allogenic cell therapy development

ISCT2023 poster showcasing simple magnetic cell separation enabled by MARS Bar for both autologous and allogenic cell therapy development.

INTRODUCTION Adoptive cell therapy has demonstrated effective clinical results in various types of cancer, leading to increased efforts in developing new drugs. However, the current manufacturing process using conventional tools is complex and often yields impure products, contributing to the high cost of cell therapy and limiting patient access. Both industry and academic cell therapy […]

TCR γ/δ+ separation from TCR α/ß+ with MARS® Bar

Application note highlighting benefits of TCR γ/δ+ separation from TCR α/ß+ with Applied Cells MARS Bar

In recent years T cell receptor (TCR) cell therapy has gained popularity due to a range of possible treatments for cancer and some infectious diseases it could provide. Since γδ T-cells constitute promising effector cell compartments for cancer immunotherapy, novel γδ T-cell-based immunotherapies are being developed. Although advancements in TCR engineering, manufacturing, and clinical applications have led to […]